Does Medicare Cover Mounjaro? Part D Coverage for T2D Tirzepatide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial

Key Takeaways

• Medicare Part D plans cover Mounjaro for type 2 diabetes (not for weight loss)
• Standard requirements include documented T2D diagnosis, A1C history, and (often) step therapy through metformin and other agents
• The 2026 Inflation Reduction Act $2,000 OOP cap limits annual Mounjaro cost for covered beneficiaries
• The Lilly Mounjaro savings card cannot be used with Medicare due to federal anti-kickback law
• Patients with both T2D and obesity should ensure the prescription is written for T2D to maintain Medicare coverage

Direct answer

Yes, Medicare Part D plans cover Mounjaro for type 2 diabetes treatment. Mounjaro is tirzepatide labeled for T2D, and T2D treatment is a fully covered Part D indication. As of May 2026, all major Medicare Part D and Medicare Advantage prescription drug plans include Mounjaro on formulary, typically at Tier 3 with prior authorization. PA criteria generally require documented T2D diagnosis, recent A1C measurement showing inadequate glycemic control, and (on most plans) step-therapy completion through metformin and at least one other oral antidiabetic. The Medicare weight-loss exclusion does not apply because Mounjaro is prescribed under the T2D label.

Table of contents

1. How Medicare treats Mounjaro vs Zepbound
2. Standard Part D PA criteria for Mounjaro
3. Step-therapy requirements
4. Tier placement across major Part D plans
5. Cost structure under the 2026 Part D benefit
6. The $2,000 OOP cap and what it changes
7. Medicare Advantage specifics
8. The Mounjaro-as-weight-loss workaround (and why it fails)
9. Appeals: the five-level Part D process
10. FAQ
11. Sources

How Medicare treats Mounjaro vs Zepbound

Tirzepatide is one molecule sold under two FDA-labeled names. Mounjaro is labeled for type 2 diabetes; Zepbound is labeled for chronic weight management and (since December 2024) obstructive sleep apnea in adults with obesity. Medicare's coverage rules treat these as different drugs because of the label.

• Mounjaro for T2D: Fully covered Part D indication; standard PA and tier rules apply
• Zepbound for weight loss: Excluded by Part D statute
• Zepbound for OSA: Covered as of the December 2024 FDA approval, subject to PA

Patients with both T2D and obesity often ask whether Mounjaro could be prescribed for both indications. The Medicare claim must be processed under the T2D indication for coverage. Prescribers should document T2D as the primary indication if T2D is the qualifying condition.

Standard Part D PA criteria for Mounjaro

Typical Part D PA elements for Mounjaro:

• Documented type 2 diabetes diagnosis (ICD-10 E11.0 - E11.9 series)
• Recent A1C measurement (within 90 days), generally ≥ 7.0% to demonstrate inadequate glycemic control on prior therapy
• Prescriber attestation of continued diet/exercise counseling
• Age ≥ 18
• Step therapy completed or exception granted
• No concurrent use of another GLP-1 receptor agonist (or GIP/GLP-1 dual agonist)
• Reauthorization at 6 months: documented A1C improvement or weight-management benefit

Some plans require type 1 diabetes exclusion documentation. Mounjaro is FDA-approved for T2D only; T1D is contraindicated.

Step-therapy requirements

Most Part D plans require step therapy before approving Mounjaro. The typical sequence:

Step	Required drug class	Documentation
1	Metformin (unless contraindicated)	Trial at maximum tolerated dose for at least 3 months
2	One additional oral T2D agent (DPP-4 inhibitor, SGLT2 inhibitor, or sulfonylurea)	3-month trial
3 (some plans)	Trial of Ozempic, Trulicity, or another GLP-1	3-month trial at therapeutic dose
4	Mounjaro approved	-

Step-therapy exceptions are available within 72 hours of request under federal regulations. The most successful exceptions cite prior treatment failures with the step drugs (intolerance, inadequate response, contraindication).

Tier placement across major Part D plans

Part D plan	Tier placement	PA required?
SilverScript Smart RX	Tier 3	Yes
Aetna Medicare Rx Select	Tier 3	Yes
Humana Walmart Value Rx Plan	Tier 3	Yes
WellCare Classic	Tier 3-4	Yes
AARP Medicare Rx Walgreens	Tier 3	Yes
Cigna Healthspring Premier Rx	Tier 3	Yes

Tier placement reflects plan-specific negotiations with Lilly and CMS-permitted formulary design. Plans can change tier placement annually (effective January 1) and rarely mid-year for cost or safety reasons.

Cost structure under the 2026 Part D benefit

The 2026 Medicare Part D benefit phases:

1. Deductible phase: Up to $590 annual deductible. Beneficiary pays full negotiated price.
2. Initial coverage phase: After deductible. Beneficiary pays copay or coinsurance as set by plan. Continues until total spending reaches the OOP cap.
3. Post-cap phase: After beneficiary OOP reaches $2,000, plan pays 100% for the rest of the year.

The coverage gap ("donut hole") and catastrophic phase from prior years are eliminated under the 2025 IRA restructuring; the new structure is simpler.

For Mounjaro at Tier 3 with $100 monthly copay: $590 deductible + $100/month copay reaches the $2,000 cap by approximately month 15 of the year. Most beneficiaries hit the cap mid-year and pay $0 for the remainder.

The $2,000 OOP cap and what it changes

Before 2025, Medicare Part D had no annual OOP cap; high-cost drugs could produce thousands in beneficiary cost over a year. The Inflation Reduction Act's $2,000 cap (indexed annually) is the largest change in Medicare prescription benefits in a generation.

The cap also enabled the Medicare Prescription Payment Plan, which lets beneficiaries spread annual OOP across 12 monthly payments rather than absorbing the full deductible upfront. For Mounjaro patients, this can smooth costs from a $590 January deductible spike to roughly $167/month for the year.

Enrollment in the Payment Plan is voluntary and requires opting in through the Part D plan during the year. Late opt-in still applies for the remaining months.

Medicare Advantage specifics

Medicare Advantage prescription drug plans (MA-PD) follow Part D rules for Mounjaro coverage. Standard MA-PD plans cover Mounjaro for T2D under the same logic as standalone Part D.

Some MA plans offer additional benefits relevant to T2D patients:

• Diabetes self-management training
• Continuous glucose monitor coverage (some plans)
• Reduced or zero cost-share on insulin (mandatory under IRA, $35/month cap)
• Care coordination programs that may streamline Mounjaro PA

The Mounjaro-as-weight-loss workaround (and why it fails)

Some patients have asked whether they can use Mounjaro for weight loss under Medicare by working with a sympathetic prescriber to write it for a "T2D-adjacent" indication.

This does not work and creates risk. Medicare claims processing checks the diagnosis codes on the prescription. If the only documented diagnosis is obesity (E66 series) without an active T2D diagnosis (E11 series), the claim is denied at adjudication. If a clinician submits a T2D diagnosis without supporting clinical evidence, that is potentially fraudulent billing.

The legitimate path for Medicare beneficiaries seeking tirzepatide for weight management without T2D:

• Zepbound under the OSA indication if you have documented sleep apnea
• Lilly Direct self-pay ($499/mo for Zepbound vials)
• Compounded tirzepatide through a 503A pharmacy (not FDA-approved)
• Out-of-pocket retail Zepbound (~$1,086/mo)

Appeals: the five-level Part D process

Medicare Part D appeals follow a structured five-level process:

1. Coverage determination redetermination by the plan. Submit within 60 days of denial. Decision within 7 days standard or 72 hours expedited.
2. Reconsideration by an Independent Review Entity (IRE). CMS contracts with an independent reviewer for second-level review.
3. Administrative Law Judge (ALJ) hearing. Available if the dollar amount in dispute exceeds the threshold ($190 for 2026).
4. Medicare Appeals Council review.
5. Federal District Court review.

For Mounjaro PA denials, most appeals resolve at levels 1 or 2. Strong appeals include A1C history, prior treatment documentation, and prescriber narrative explaining medical necessity.

Contrary view: why Medicare's tirzepatide coverage is rational

Medicare's split treatment of tirzepatide (Mounjaro covered, Zepbound mostly not) gets criticized as arbitrary: same molecule, different rules. The defensible response:

Medicare's statutory exclusion targets drugs prescribed for weight loss specifically, dating to a different generation of weight-loss medications. The Mounjaro/Zepbound split isn't arbitrary; it reflects which clinical indication the label addresses. T2D coverage has a long history in Medicare; weight-loss coverage has been explicitly excluded for over 20 years.

The recent OSA approval shows the system can adapt: when tirzepatide gained a new FDA-approved indication outside weight loss, Medicare coverage followed. The criticism is partly about the underlying weight-loss exclusion (a legitimate policy debate) rather than Medicare's application of it.

For patients, the practical answer is: get the prescription written under a covered indication if you qualify, and pursue self-pay if you don't.

Decision framework

If you have Medicare and T2D: Mounjaro is covered. Submit complete PA with A1C history and prior therapy documentation.

If you have Medicare without T2D but with obesity: Mounjaro is not the right path. Look at Zepbound for OSA (if applicable) or self-pay.

If denied: Read the reason code. Request redetermination at level 1, then IRE reconsideration at level 2 if needed.

If step therapy is the barrier: File exception with prior treatment documentation. 72-hour response required.

FAQ

Does Medicare cover Mounjaro? Yes, for T2D under Part D.

Does Medicare cover Mounjaro for weight loss? No. Medicare's weight-loss exclusion applies.

What does Mounjaro cost on Medicare? Tier 3 copay typically $47-$120 monthly. Bounded by the $2,000 annual OOP cap.

Can I use the Mounjaro savings card with Medicare? No. Manufacturer copay cards are not permitted with Medicare.

What PA does Medicare require? T2D diagnosis, A1C history, and (often) step therapy through metformin and other agents.

How do I appeal? Five-level Part D process. Most appeals resolve at level 1 or 2 with proper documentation.

What if I have both T2D and obesity? Mounjaro under the T2D indication is covered. Document T2D as primary.

Does Medicare Advantage cover Mounjaro differently? MA-PD plans follow Part D rules but may add care-coordination benefits.

Sources

1. FDA. Mounjaro (tirzepatide) prescribing information. Updated 2024.
2. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). NEJM. 2021.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). The Lancet. 2021.
4. Social Security Act, Section 1860D-2(e)(2)(A). Part D coverage exclusions.
5. Centers for Medicare & Medicaid Services. Part D Manual, Chapter 6: Part D Drugs and Formulary Requirements. Updated 2025.
6. Inflation Reduction Act of 2022. Public Law 117-169. Part D OOP cap and Prescription Payment Plan provisions.
7. American Diabetes Association. Standards of Care in Diabetes 2026.
8. Eli Lilly. Mounjaro and Mounjaro Savings Card terms. Accessed May 2026.
9. CMS. Part D appeals process guidance. Updated 2024.
10. Kaiser Family Foundation. Medicare Part D in 2026: Plan benefits, costs, and beneficiary OOP. 2026.
11. FDA. Zepbound prescribing information. Updated 2024.
12. Malhotra A et al. Tirzepatide for Obstructive Sleep Apnea and Obesity. NEJM. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with independent licensed clinicians and U.S.-based pharmacies. We are not a Medicare plan, a Part D sponsor, or a federally authorized Medicare counselor. Confirm coverage with your specific plan or 1-800-MEDICARE.

Compounded Medication Notice. Compounded tirzepatide is not FDA-approved and is not therapeutically equivalent to Mounjaro or Zepbound. Medicare does not cover compounded medications. FormBlends offers compounded tirzepatide through licensed 503A pharmacies for patients who choose this path under clinical supervision.

Results Disclaimer. Cost figures and PA criteria reflect the 2026 Medicare Part D benefit structure as currently legislated. Plan-specific tier placement and copay rates vary. Your individual cost depends on your plan, deductible position, and OOP cap status.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Trulicity are registered trademarks of their respective manufacturers (Novo Nordisk; Eli Lilly). Medicare is a federal health insurance program. Named Part D plans are registered trademarks of their respective owners. FormBlends has no affiliation with CMS, Medicare, or any Part D plan.